RxDoctor Payments Data

Michael Watto, DO

Family Medicine · Franklin, NHNPI 1386704039

Payments from drug & device makers

$468in general payments, 2019–2025

Across 27 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$191
  • AstraZeneca$161
  • Pfizer$48
  • Lilly USA, LLC$20
  • Johnson & Johnson$16
  • Sanofi Pasteur Inc.$16
  • plus $16 from 1 others

What the payments were for

  • Food & beverage$43794%
  • Education$306%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$191
AstraZeneca3$161
Pfizer3$48
Lilly USA, LLC1$20
Johnson & Johnson2$16
Sanofi Pasteur Inc.1$16
GSK1$16

How this compares

$468 in reported general payments places this provider in the 75th percentile of 397 family medicine providers in New Hampshire.

See all family medicine providers in New Hampshire

Medicare billing

Part B allowed, 2024
$10,701
Medicare patients
118
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$57,318
OxycontinOxycodone Hcl41$54,920
JardianceEmpagliflozin38$39,678
OzempicSemaglutide40$37,466
TrulicityDulaglutide27$26,302
FarxigaDapagliflozin Propanediol19$22,003
Spiriva HandihalerTiotropium Bromide13$10,122
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$8,148
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$7,773
Atrovent HfaIpratropium Bromide11$6,800
Breo ElliptaFluticasone/Vilanterol15$6,616
Tresiba Flextouch U-100Insulin Degludec11$5,296
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$4,231
Pregabalin34$2,877
Gabapentin129$2,798

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$48$57,31873 claims
Lilly USA, LLCTrulicity$20$26,30227 claims
AstraZenecaFarxiga$161$22,00319 claims
GSKAnoro Ellipta, Breo Ellipta$16$14,76428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 397 family medicine providers in New Hampshire.

Other family medicine in Franklin

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →